Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

JENTADUETO XR

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Standard Dose
2.5MG;1GM
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview JENTADUETO XR is listed in Drugs@FDA under application 208026 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 2.5MG;1GM Sponsor BOEHRINGER INGELHEIM Submission history Latest submission status date: 2023-06-20 00:00:00.

Structured Monograph

Clinical summary

Approval overview JENTADUETO XR is listed in Drugs@FDA under application 208026 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient LINAGLIPTIN; METFORMIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 2.5MG;1GM Sponsor BOEHRINGER INGELHEIM Submission history Latest submission status date: 2023-06-20 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.